Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23195547 | 0.81 | KDM4E (0.65) | KDM4EPOLB | |
| SCHEMBL20666239 | 0.81 | DYRK1A (0.48) | MEN1KMT2ATDP1 | |
| SCHEMBL24985286 | 0.81 | PDE4A (0.43) | KDM4EPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL23195551 | 0.78 | LMNA (0.43) | KDM4ETDP1 | |
| SCHEMBL26525609 | 0.75 | POLB (0.45) | KDM4EPDE4DPDE4AMEN1POLB | |
| SCHEMBL24345422 | 0.75 | HRH1 (0.44) | — | |
| SCHEMBL23195545 | 0.75 | MEN1 (0.45) | KDM4EPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL24986029 | 0.74 | KDM4E (0.58) | KDM4EPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL20064620 | 0.73 | HRH1 (0.43) | — | |
| SCHEMBL12789731 | 0.72 | TDP1 (0.53) | KDM4EPDE4DPDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230125803-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARM INC (US) | 2023-04-27 | — | — | US | disclosed |
| US-11572367-B2 | Antiviral heterocyclic compounds | ENANTA PHARMACEUTICALS, INC. (US) | 2023-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572367-B2 | Antiviral heterocyclic compounds | ACE, HPRT1, ACE2 | KDM4E 1648/4885PDE4D 2028/4885PDE4A 961/4885 |
| US-20230125803-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ACE, HPRT1, ACE2 | KDM4E 1648/4885PDE4D 2028/4885PDE4A 961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.